Disclosures 9/25/2012. Emerging Biomarkers for Risk Stratification, Prognosis and Prediction of Treatment Responses in Colorectal Carcinoma (CRC)
|
|
- Suzanna Woods
- 5 years ago
- Views:
Transcription
1 Emerging Biomarkers for Risk Stratification, Prognosis and Prediction of Treatment Responses in Colorectal Carcinoma (CRC) Disclosures 21 st ANNUAL SYMPOSIUM ON MOLECULAR PATHOLOGY Clinical Applications of Genomic Medicine September 19, 2012 I have no conflicts of interest Dhananjay Chitale, MD Division Head, Molecular Pathology and Genomic Medicine Director, Tissue Biorepository Senior Staff Surgical Pathologist Clinical Assistant Professor, Wayne State University School of Medicine Henry Ford Hospital, Detroit, MI Outline for today's talk 1. The epidemiology of colorectal cancer (CRC) 2. Understanding of CRC at molecular level a. Correlation with morphologic alterations in the course of the progression to malignancy 3. Global molecular alterations present in CRC a. Risk stratification, prognosis b. Predictive of treatment responses 4. Specific genetic alterations and signal pathway deregulation a. Risk stratification, prognosis b. Predictive of treatment responses 1. Potential utility in the management of patients using current adjuvant therapy (5FU/LV, Irinotecan, Oxaliplatin etc.) 2. Targeted therapy (KRAS, BRAF, PI3CA etc.) 5. Multigene signature assays 6. Pharmacogenomics (5FU/LV, Irinotecan, Oxaliplatin etc.) The 20 Most Commonly Diagnosed Cancers Worldwide, 2008 Estimates Cancer Research UK 2011 Registered charity in England and Wales ( ) and Scotland (SC041666) The 20 Most Common Causes of Death from Cancer Worldwide, 2008 Estimates 2010, American Cancer Society, Inc. Cancer Research UK 2011 Registered charity in England and Wales ( ) and Scotland (SC041666) 1
2 American Cancer society DATA SEER DATA Decreasing incidence of CRC attributed to colonoscopy, FOBT / FIT Conclusion from the American Cancer Society statistics Third in incidence as well as cancer related mortality for both men and women in most western countries. Incidence of CRC is declining due to screening (colonoscopy, Guaiac stool test etc) However, the long term survival has not changed significantly when compared stage to stage better understanding of the molecular biology and pathogenesis of CRC there is a need to identify molecular targets CRC facts CRC facts 65 85% are sporadic no family history Sporadic Hereditary Approximately 20% of patients present with metastatic disease Metastatic colon cancer 5 year survival rate of only 11%. An additional 30% to 40% develop metastasis during the course of their disease. 15% and 35% major hereditary component Strong CRC in first or second degree relatives fourth of these are highly penetrant (< 5%) Single gene mutation cancer syndrome CRC develops as multistep progression Genotypic and phenotypic (Vogelstein model) 65 85% 15 35% Overall 5 year survival: ~65% CRC not a single disease but heterogeneous complex of diseases Each CRC is caused by distinctive genetic/ epigenetic background 2
3 Risk stratification traditional. so how do we stratify risk? Clinical (proximal versus distal) Pathological Grade: well moderate versus poorly differentiated Mucinous versus nonmucinous Lymphovascular invasion, perineural invasion Pathological stage Clinical response to treatment is diverse, even if their clinicopathological parameters seems similar, especially early stage cancers pt1 pt2 pt3 pt4 Adenoma carcinoma Sequence Risk stratification molecular pathways and biomarkers Normal TVA HG dysplasia CA There is substantial evidence that treatment response is dependent on the aberrations in the tumor itself and genetic background of the individual (germline) as well. Adenoma carcinoma Sequence Molecular pathways and biomarkers Reflect underlying mechanisms of carcinogenesis which will help identify potential therapeutic targets Inactivation Mutations 18q loss TP53 of APC CIN defect: in KRAS DCC,DPC4 17q loss 5q loss Normal TVA HG dysplasia CA Genomic instability global cellular events such as Chromosomal instability (CIN) Micorsatellite instability (MSI) CpG island methylator phenotype (CIMP) Single molecular events for predicting response to targeted therapies against those molecules e.g. KRAS, BRAF, PI3KCA etc Non random Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:
4 Chromosomal instability (CIN) Chromosomal instability (CIN) Numerical chromosomal alterations are referred to CIN leading to carcinogenesis through loss of tumor suppressors genes loss of heterozygosity (LOH) the suppressor pathway copy number gains of oncogenes. CIN involves large proportion of CRC (~80 85%), mostly MSIstable tumors Causes of CIN are heterogeneous Chromosome cohesion e.g. Rad21/SCC1, SCC3, Securin Mitotic checkpoint defects e.g. Mutations in genes encoding mitotic checkpoint proteins such as BUB1 and BUB1B (BUBR1) Centrosome amplification, cytokinesis failure e.g. Amplification of AURKA (Aurora kinase A, STK15/BTAK), a centrosome associated serine threonine kinase Kinetochore microtubule attachment dynamics Dysregulation of cell cycle proteins e.g. Mdm2, TP53 1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319: Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer.Watanabe et al J Clin Oncol 2012:30: Mechanisms of Chromosomal Instability. Current Biology 20, R285 R295, March 23, Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319: Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer.Watanabe et al J Clin Oncol 2012:30: Mechanisms of Chromosomal Instability. Current Biology 20, R285 R295, March 23, 2010 Chromosomal instability (CIN) DNA Repair Defects Microsatellite instability Allelic losses are common in CRC with high frequencies, such as on chromosomes 17p p53 gene (75% CRC), other p53 allele had been inactivated by mutation 5q APC gene Allelic deletions in up to 50% of CRC and in about 30% of adenomas, respectively and truncating mutations are found in 63% and 60% of adenomas and carcinomas, respectively 18q Deleted in colorectal carcinoma gene (DCC)~70% SMAD 4 and SMAD 2 genes While looking for LOH events using microsatellite markers, a second completely unrelated type of genomic instability was detected This type of hypermutability, termed MSI or RER present in about 15% of all colorectal tumors Functional loss of MLH1 due to promoter methylation and gene silencing in sporadic CRCs Most near diploid in more than 90% of cancers in Lynch syndrome (~3% of all CRC) mutations in any of the mismatch repair genes, MSH2, MLH1, MSH6, PMS2 (less common PMS1, MSH3) 1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319: Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer. Watanabe et al J Clin Oncol 30: Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396: Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10:13 27; DOI: /jmoldx Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer. Watanabe et al J Clin Oncol 30: DNA Repair Defects Microsatellite instability Aberrant DNA Methylation Epigenetic changes methylation of promotor MSI is the manifestation of the loss of protein function one or more DNA mismatch repair proteins (MMR proteins) MSI H >30% unstable loci in a panel of 5 10 loci (monodinucleotide) 5 mononucleotides (BAT 25, BAT 26, NR 21, NR 24, MONO 27) MSI leads to inactivation of tumor suppressor genes Clusters of cytosine residues followed by a guanosine (CpG), sequences are present in about 50 70% of promoters in the human genome Many genes are inactivated with transcriptional silencing by hypermethylation at CpG islands (1998) MLH1 was inactivated by epigenetic modification of its promoter in most of the sporadic tumors with MSI. Sinicrope F A, Sargent D J Clin Cancer Res 2012;18: Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hmlh1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95: Kane MF, Loda M, Gaida GM, et al. Methylation of the hmlh1 promoter correlates with lack of expression of hmlh1 in sporadic colon tumors and mismatch repair defective human tumor cell lines. Cancer Res. 997;57:
5 CIMP CpG island methylator phenotype Classifications CIMP CpG island methylator phenotype CIMP high colorectal tumors have a distinct clinical, pathological, and molecular profile associations with proximal tumor location, female sex, poor differentiation, MSI H high BRAF and low TP53 mutation rates The serrated pathway of tumorigenesis has been suggested in the development of CIMP high CRC 15% Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10:13 27; DOI: /jmoldx CIMP At the present time, the panel of methylation markers and the method of assessment of CIMP is not standardized Few sensitive and specific markers to identify CIMP high using MethyLight technology CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1 Several published studies have combined analysis of these genomic instability profiles to subclassify CRC Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10:13 27; DOI: /jmoldx MSI/CIMP classification Histopathologic changes in CRC carcinogenesis Sporadic MSI H pathways (CIMP) Sessile serrated polyp Carcinoma Sequence HNPCC/Lynch syndrome MLH1 methylation + BRAF V600E mutation Normal MLH1 methylation Dysplastic crypt APC β catenin AXIN2 BRAF mutations >KRAS) Mutational inactivation of genes with microsatellites: TGF βiir, BAX Sessile Serrated polyp/ Carcinoma adenoma Inactivation of tumor suppressor genes by promoter hypermethylation APC β catenin AXIN2 Mutational inactivation of genes with microsatellites: TGF βiir, BAX Normal Dysplastic crypt Tubular adenoma Carcinoma CIMP /MSI subtype is the most common Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10:13 27; DOI: /jmoldx MMR Mutational inactivation Familial MSI H pathways (HNPCC) KRAS mutations adenomatous polyp Carcinoma Sequence Adapted from The Molecular Basis of Cancer, Saunders, Elsevier, 3 rd edition P53 mutations 5
6 DNA Repair Defects Evolving concept of molecular pathways of CRC development Tumor suppressor pathway Hypermutator pathway Sinicrope F A, Sargent D J Clin Cancer Res 2012;18: Risk and prognostic stratification What do these global genomic changes mean in the grand scheme of risk and prognostic stratification? CIN high (especially 18q): worst survival 18qLOH/SMAD4 loss Poor prognosis in CIMP low patients regardless of MSI screening status Poor prognosis in CIMPhigh patients with MSS CIN low : better survival MSI+ cancers have a better prognosis 1. Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer. Watanabe et al J Clin Oncol 30: The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status. Anna M. Dahlin et al, Clin Cancer Res; 16(6); Prognostic biomarkers in CRC Predictive biomarkers in CRC Despite the clear association of MSI and CIN with prognosis, these markers have not yet been adopted into routine clinical decision making Colorectal cancer molecular biology moves into clinical practice, Colin C Pritchard,William M Grady Gut 2011;60:116e129. doi: /gut Colorectal cancer molecular biology moves into clinical practice, Colin C Pritchard,William M Grady Gut 2011;60:116e129. doi: /gut
7 CIN Can we use CIN, CIMP, MSI in clinical decision making? Lack of Gold Standard and Uniform Methods, Definition, and Criteria Limitations: 1. Markers and criteria for CIN have not been standardized 2. No conclusive studies predicting response rates based on CIN+/ status 1. Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Colorectal cancer molecular biology moves into clinical practice Colin C Pritchard,1 William M Grady Gut 2011;60:116e129. doi: /gut CIMP Limitations: 1. Lack of a universally accepted definition of the methylator phenotype Ogino CIMP Marker Panel (MLH1, p16, CRABP1, CACNA1G, and NEUROG1) Laird CIMP Marker Panel (CACNA1G, NEUROG1, IGF2, RUNX3, and SOCS1) 2. Considerable overlap between CIMP and sporadic MSI tumors adds to the challenge of incorporating CIMP status into clinical trials and clinical decision making MSI Limitations: 1. Despite the presence of the recommended panel of markers (the NCI panel) markers used for studies on MSI are still not uniform to draw reproducible conclusions. Moderate evidence: 1. Shown to predict adverse outcome with 5 FU 2. Improved outcome with Irinotecan Evidence not enough to recommend routine MSI testing as predictive marker 1. Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Colorectal cancer molecular biology moves into clinical practice Colin C Pritchard,1 William M Grady Gut 2011;60:116e129. doi: /gut Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10: Colorectal cancer molecular biology moves into clinical practice Colin C Pritchard,1 William M Grady Gut 2011;60:116e129. doi: /gut CIN+CIMP+MSI+ mutations Genomic instability Role of specific genetic alterations and signal pathway deregulation There is an accumulation of mutations in specific genes resulting in deregulation of specific cell signalling pathways differentiation apoptosis immortalisation angiogenesis invasion CIN CIMP MSI WNT TGF β PI3K RTK RAS TP53 7
8 Diversity and frequency of genetic changes leading to deregulation of signalling pathways in CRC. The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 Non Hypermutated Preferred pathways Hypermutated (MSI H) Mutation frequencies in human CRC. WNT signaling 92% RTK RAS signaling 59% PI3K signaling 50% TGF β signaling 27% P53 signaling 64% WNT signaling 97% TGF β signaling 87% RTK RAS signaling 80% PI3K signaling 53% P53 signaling 47% The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 Mutation frequencies in human CRC. Evolving concept of molecular pathways of CRC development After removal of non expressed genes Hypermutated tumors (16%) ACVR2A 63% APC 51% TGFBR2 51% BRAF 46% MSH3, MSH6 40% MYO1B, TCF7L2 31% CASP8, CDC27, FZD3 29% MIER3, TCERG1 29% Non hypermutated tumors (84%) APC 81% TP53 60% KRAS 43% PIK3CA 18% FBXW 11% SMAD4 10% TCF7L2 9% NRAS 9% The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 Annu Rev Pathol MechDis 2011, 6: Molecular pathology of CRC 8
9 Can we use somatic mutation in clinical decision making? Somatic molecular alterations in cell signaling pathways provide opportunities for targeted therapy for personalized medicine and have been used successfully many tumors e.g. TKI Lung cancer Imatinib CML, GIST WNT pathway Small molecule inhibitors of this pathway are still in the preclinical setting Therefore, despite the critical and universal role of WNT, there is no clinical role for APC or CTNB1 mutation in treatment selection or prognosis The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 Colorectal cancer molecular biology moves into clinical practice, Colin C Pritchard,William M Grady Gut 2011;60:116e129. doi: /gut TGFβ pathway TP53 Deregulation of TGFβ signaling in many CRC Loss of SMAD4 tumor suppressor gene Lymph node metastasis Still, there is no definite clinical role for any genetic markers is in the TGFβ signaling 18qLOH associated with poor prognosis Role as predictive marker still in clinical trials (ECOG5202) MSI H TP53 mutations are noted in ~50% of all the CRC Like APC, key tumor suppressor gene No prognostic or predictive role in the clinical setting The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature
10 Overlapping mutations Mutually exclusive EGF signaling ERBB2/RAS/RAF/RAF/MAPK Constitutive activation by KRAS mutations codons 12,13 40% BRAF mutations codons % MSI H Prognostic biomarkers in CRC EGF signaling PI3K/Akt pathway PIK3CA mutations 20% PTEN loss 30% The Cancer Genome Atlas Network Nature 487, (2012) doi: /nature11252 Colorectal cancer molecular biology moves into clinical practice, Colin C Pritchard,William M Grady Gut 2011;60:116e129. doi: /gut Predictive biomarkers in CRC EGF signaling Mechanism of action anti EGFR Four large phase III randomized trials established the association of KRAS mutation and lack of benefit from anti EGFR therapy in metastatic CRC Colorectal cancer molecular biology moves into clinical practice, Colin C Pritchard,William M Grady Gut 2011;60:116e129. doi: /gut Gut 2011;60:116e129. doi: /gut Predictive markers currently in clinical practice mcrc First negative predictor for a targeted therapy 1. Testing for mutations in KRAS codon 12, 13 in exon 2 negative predictor to anti EGFR therapy CLIA certified lab, no specific methodology recommended, performed on FFPE or fresh tissues 2. BRAF mutations negative predictor to anti EGFR therapy (insufficient evidence) CLIA certified lab, no specific methodology recommended, performed on FFPE or fresh tissues 3. MSI testing should be considered CRC patients <50 yrs. or with stage II disease Stage II may have good prognosis and do not benefit from 5 FU neoadjuvant therapy Benefit from Irinotecan containing regimens NCCN Clinical Practice Guidelines for Oncology: Colon Cancer v
11 A C B D 9/25/2012 K ras testing Formalin fixed, paraffin embedded tissue Fresh frozen tissue HFH experience: KRAS codon 12,13+ CRC: 41% (212/512) No significant ethnic difference FFPE tissue Fresh frozen tissue B raf testing HFH MSI BRAF+ KRAS+ hmlh1 H+ AA (19) CA(19) Others(4) Total(42) Most MSI H tumors were sporadic CRC with frequent BRAF mutations, hmlh1 M and occurred in RC of elderly CA women Forward 34G>T; G12C 1799T>A; V600E Reverse Reverse Forward Testing methodologies and sensitivity MSI H Direct sequencing (Sanger sequencing) ~25% Locked Nucleic acid PCR sequencing ~1% (Arcila M, et al. J Mol Diagn 13:64 73, 2011 BAT 26 NR 21 BAT 25 MONO 27 Tumor NR 21 BAT 26 BAT 25 MONO 27 Normal NR 24 NR 24 ARMS Amplification Refractory Mutation System Qiagen FDA approved test ~1% Sequenom based assays (MALDI TOF) ~5 10% H & E Loss of MSH2 Colonic adenocarcinoma IHC Multigene signature assays guiding selection for current adjuvant therapy in early stage colorectal cancers (stage II: T3 T4, N0,M0) Currently not in NCCN recommendation Loss of MSH6 Positive MLH1 NCCN Clinical Practice Guidelines for Oncology: Colon Cancer v
12 Stage II Colon Cancer Which patient should receive adjuvant chemotherapy? The 12 Gene Oncotype DX Colon Cancer Recurrence Score Assessment of recurrence risk following surgery Identification of patients who would benefit from 5FU/LV Independent clinical value in the context of other measures such as T stage and MMR Optimized for FFPE colon tumor tissue High risk for recurrence Benefit from chemorx Kerr et al., ASCO 2009, #4000 Recurrence Score STROMAL FAP INHBA BGN GADD45B CELL CYCLE Ki 67 C MYC MYBL2 RS = 0.15 x Stromal Group 0.30 x Cell Cycle Group x GADD45B Reference Genes ATP5E GPX1 PGK1 UBB VDAC2 O Connell et al JCO 28:3937 Kerr et al., ASCO 2009, #4000 Oncotype DX Colon Cancer Assay Patient Report QUASAR Validation Study Clinical validation study analyzed 1,436 patients with stage II colon cancer The Recurrence Score is a validated multi gene RT PCR clinical assay which independently and quantitatively predicts individual recurrence risk The continuous RS will have the greatest clinical utility for T3, MMR proficient patients, who constitute the majority of stage II colon cancer (~70% of pts) Prognostic assay for assessing risk of recurrence O Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of stage II/III colon cancer patients treated with surgery alone or surgery plus adjuvant 5 FU/LV. J Clin Oncol. 2010; 28: Oncotype DX Colon Cancer Assay Predictive? The treatment score was not predictive of chemotherapy benefit Not ready for predicting treatment response ColoPrint 18 gene signature based assay for CRC 18 gene set to predict high vs low recurrence risk patients. MCTP1, LAMA3, CTSC, PYROX D1, EDEM1, IL2RB, ZNF697, SLC6A11, IL2RA, CYFIP2, PIM3, LIF, PLIN3, HSD3B1, ZBED4, PPARA, THNSL2, CA4388O2 Requires fresh frozen samples Able to predict the development of distant metastasis in stage II CRC patients Facilitates the identification of patients who may be safely managed without chemotherapy No studies on predicting response yet J Clin Oncol. 2011;35: J Clin Oncol. 2011;29: Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. J Clin Oncol 29: 2011 (suppl 4; abstr 358) 12
13 Previstage Guanylyl Cyclase C test for staging CRC 25 30% of pn0 patients develop recurrent disease Likely due to sampling limitations in histology examination underestimating occult lymph node metastasis GCC (GUCY2C) is expressed in primary and metastatic CRC Expression of GCC by qrt PCR to detect occult lymph node metastases in FFPE tissues Prospective study of 257 patients with pn0 CRC showed expression of GUCY2C in histologically negative lymph nodes independently associated with time to recurrence and disease free survival in patients with pn0 colorectal cancer Previstage Guanylyl Cyclase C test for staging CRC 241 patients with stage II colon cancer without adjuvant chemotherapy RT qpcr for GCC mrna in FFPE lymph node tissues Preliminary results detection of GCC mrna in LNs associated with risk of disease recurrence in patients with untreated stage II CRC No studies on predicting response yet 1. Previstage GCC test for staging patients with colorectal cancer. Expert Rev Mol Diagn September ; 8(5): Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease Free Survival in pn0 Colorectal Cancer. JAMA. 2009;301(7): Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Ann Surg Oncol (2011) 18: Pharmacogenomics (PG) Heritable traits related to drug delivery and drug action Pharmacogenomics The therapeutic drug level affected by Pharmacokinetics What body does to drugs? (drug delivery) Clearance Half Life Bioavailability Metabolism PK PG Polymorphisms in enzymes / binding proteins required for transporting, metabolizing, excreting the drug PD Pharmacodynamics What drugs do to the body (drug action) Most drug actions mediated via receptors binding proteins enzymes. 1. Renal or hepatic impairment 2. Polymorphic metabolism 3. Environmental influences Pharmacogenomics (PG) Heritable traits related to drug delivery and drug action Polymorphisms & irinotecan Drug metabolizing enzyme UGT1A1 Inactivates SN 38, the active species derived from irinotecan Reduced activity of UGT1A1 causes toxicity FDA APPROVED PG Polymorphisms & 5 FU Folate metabolism Pharmacogenomics in treatment of CRC PK PD Polymorphisms & Oxaliplatin Pharmacogenomics in colorectal cancer: The first step for individualized therapy World J Gastroenterol 2007 November 28; 13(44): Pharmacogenomics in colorectal cancer: The first step for individualized therapy World J Gastroenterol 2007 November 28; 13(44):
14 Take home message CIN+ cancers are associated with worse prognosis, MSI+ cancers have a better prognosis 18q LOH + tumor also have a worse prognosis Key pathways that drive colorectal cancer WNT signalling TGFβ signalling EGFR signaling Ras/Raf/MAPK and phosphatidylinositol 3 kinase (PI3K) Take home message Currently, only KRAS mutations in codon 12/13 are the highly validated predictive marker for resistance to anti EGFR drugs in treating CRC BRAF V600E mutation is likely to be a second predictive marker. MSI H shown to predict adverse outcome with 5 FU, improved outcome with Irinotecan Currently there are no predictive multi gene assays available The role of CRC molecular biomarkers in clinical decision making is likely to expand as more targeted drugs become available. Pharmacogenomics will likely play a role in selection and dosing of chemotherapeutic agents Personalized predictive pathology Beyond morphology, margins and staging Morphogenomics and Morphoproteomics A Role for Anatomic Pathology in Personalized Medicine. Robert Brown Arch Pathol Lab Med Vol 133, April 2009 References 1. The Molecular Basis of Cancer, Saunders, Elsevier, 3rd edition Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease Free Survival in pn0 Colorectal Cancer. JAMA. 2009;301(7): Chromosomal Instability (CIN) Phenotype, CIN High or CIN Low, Predicts Survival for Colorectal Cancer. Watanabe et al J Clin Oncol 30: Colorectal cancer molecular biology moves into clinical practice, Colin C Pritchard,William M Grady Gut 2011;60:116e129. doi: /gut Comprehensivemolecular characterization of human colon and rectal cancer Nature 487, (2012) doi: /nature Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Ann Surg Oncol (2011) 18: Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hmlh1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95: Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. J Clin Oncol 29: 2011 (suppl 4; abstr 358) 9. J Clin Oncol. 2011;29: J Clin Oncol. 2011;35: Kane MF, Loda M, Gaida GM, et al. Methylation of the hmlh1 promoter correlates with lack of expression of hmlh1 in sporadic colon tumors and mismatch repair defective human tumor cell lines. Cancer Res. 997;57: Kerr et al., ASCO 2009, # Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396: Molecular Classification and Correlates in Colorectal Cancer. Ogino S, Goel A. J Mol Diagn 2008, 10:13 27; DOI: /jmoldx Molecular Genetics of Colorectal Cacner, Fearon. Annu Rev Pathol MechDis 2011, 6: Molecular pathology of CRC 16. Morphogenomics and Morphoproteomics A Role for Anatomic Pathology in Personalized Medicine. Robert Brown Arch Pathol Lab Med Vol 133, April NCCN Clinical Practice Guidelines for Oncology: Colon Cancer v1.2013, O Connell et al JCO 28:3937, Kerr et al., ASCO 2009, # O Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of stage II/III colon cancer patients treated with surgery alone or surgery plus adjuvant 5 FU/LV. J Clin Oncol. 2010; 28: Pharmacogenomics in colorectal cancer: The first step for individualized therapy World J Gastroenterol 2007 November 28; 13(44): Previstage GCC test for staging patients with colorectal cancer. Expert Rev Mol Diagn September ; 8(5): Sinicrope F A, Sargent D J Clin Cancer Res 2012;18: The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status. Anna M. Dahlin et al, Clin Cancer Res; 16(6); Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:
Development of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationColorectal cancer molecular biology moves into clinical practice
1 Department of Laboratory Medicine, University of Washington, Washington, USA 2 Clinical Research Division, Fred Hutchison Cancer Research Center, Washington, USA 3 Department of Medicine, University
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationLa genetica del carcinoma colo-rettale
La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona OUTLINE What s new in colorectal cancer? Pathological Markers
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationBiology of cancer development in the GI tract
1 Genesis and progression of GI cancer a genetic disease Colorectal cancer Fearon and Vogelstein proposed a genetic model to explain the stepwise formation of colorectal cancer (CRC) from normal colonic
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationMolecular Diagnosis for Colorectal Cancer Patients
Molecular Diagnosis for Colorectal Cancer Patients Antonia R. Sepulveda MD, PhD, FCAP October, 20, 2010 www.cap.org Welcome to the PHC Webinar Series This talk on The Molecular Diagnosis for Colorectal
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationAgenda 8:30 AM. Jennifer L. Hunt
Agenda Topic Introduction Terence J. Colgan Jennifer L. Hunt Time 8:30 AM Pre-analytic Variables in Molecular Testing Philip A. Branton 8:40 AM Carcinoma of Unknown Primary Site Is Gene Expression Profiling
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationMarcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationHisto-prognostic factors what histopathology has to offer for clinical decision making
Histo-prognostic factors what histopathology has to offer for clinical decision making Daniela E. Aust Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationThe silence of the genes: clinical applications of (colorectal) cancer epigenetics
The silence of the genes: clinical applications of (colorectal) cancer epigenetics Manon van Engeland, PhD Dept. of Pathology GROW - School for Oncology & Developmental Biology Maastricht University Medical
More informationMolecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma
Molecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma Andrew C. Nelson, M.D., Ph.D. Divisions of Anatomic & Molecular Pathology Department of Laboratory Medicine & Pathology
More informationDisclosure slide I Member of advisory board for AMGEN, ROCHE, BOEHRINGER I Speaker honoraria from FALK Pharma, Pfizer, Lilly and ROCHE I Third party f
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationClinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer
Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer Shuji Ogino, M.D., Ph.D. Associate Professor of Pathology Harvard Medical School Brigham and Women s Hospital Dana-Farber
More informationEarly (and not so early) colorectal cancer: The pathologist s point of view
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationOncotype DX : Scientific Publications and Presentations
Oncotype DX : Scientific Publications and Presentations www.oncotypedx.com Oncotype DX : Scientific Publications and Presentations A Tool for Individualized Colon Cancer Treatment The Oncotype DX Colon
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationArzu Ensari, MD, PhD Department of Pathology Ankara University Medical School
Precursors of Colorectal Carcinoma Arzu Ensari, MD, PhD Department of Pathology Ankara University Medical School Hyperplastic polyp Adenomatous polyp Colorectal carcinoma IBD-associated (1-2%) Sporadic
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationGenetic Modifiers of Chemotherapy for Colorectal Cancer
Genetic Modifiers of Chemotherapy for Colorectal Cancer September 27, 2011 John M. Carethers, M.D. Professor of Internal Medicine University of Michigan 1,233,700 cases/year Worldwide ~146,000 cases/year
More informationOncotype DX DX : Colon Cancer Assay: Scientific Publications and Presentations.
Oncotype DX DX : Colon Cancer Assay: Scientific Publications Scientific and Presentations Publications and Presentations www.oncotypedx.com Oncotype DX : Scientific Publications and Presentations A Tool
More informationDr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS
Molecular Profiling of Cancer Cells Strategies for Developing Biomarkers for Targeted Therapies of Cancer Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Head, Department of Molecular Medicine and
More informationIntegration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium
Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Ulrike Peters Fred Hutchinson Cancer Research Center University of Washington U01-CA137088-05, PI: Peters
More informationThe Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer
Gut and Liver, Vol. 9, No. 2, March 215, pp. 22-27 ORiginal Article The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer Ki Joo Kang*, Byung-Hoon Min, Kyung Ju Ryu, Kyoung-Mee
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationColon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP
Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.
More informationMicrosatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France
Microsatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France Content - Colorectal cancer context - CRC molecular classification
More informationMolecular Subtyping of Endometrial Cancer: A ProMisE ing Change
Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change Charles Matthew Quick, M.D. Associate Professor of Pathology Director of Gynecologic Pathology University of Arkansas for Medical Sciences
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More information1 Molecular Biology of Colon
Chapter 1.qxd 4/3/06 6:39 PM Page 1 1 Molecular Biology of Colon Cancer William M. Grady, MD Summary Colorectal cancer affects approx 140,000 people in the United States each year, resulting in more than
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationClinical, Pathologic and Molecular Updates
Colorectal Cancer: Clinical, Pathologic and Molecular Updates Joanna A. Gibson, M.D./Ph.D. Yale University School of Medicine/Yale New Haven Hospital, Department of Pathology Gastrointestinal, Pancreaticobiliary
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationWhere are we in 2013?
The Use of Gene Profile Testing in the Adjuvant Therapy of Stages II & III Colon Cancer: Where are we in 2013? Howard S. Hochster, MD Professor of Medicine, Yale School of Medicine Associate Director,
More informationClinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability
The Korean Journal of Pathology 29; 43: 428-34 DOI: 1.4132/KoreanJPathol.29.43.5.428 Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability Sang Kyum Kim Junjeong
More informationCitation for published version (APA): Bleeker, W. A. (2001). Therapeutic considerations in Dukes C colon cancer s.n.
University of Groningen Therapeutic considerations in Dukes C colon cancer Bleeker, Willem Aldert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: multigene_expression_assay_for_predicting_colon_cancer_recurrence 1/1/2019 NA 1/1/2020 1/1/2019 Description
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationCase Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr
Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationTHE CROSSROADS: Drug Development, Biomarkers, and Colorectal Cancer
THE CROSSROADS: Drug Development, Biomarkers, and Colorectal Cancer SANJAY GOEL, M.D., M.S. PROFESSOR OF MEDICINE ALBERT EINSTEIN COLLEGE OF MEDICINE MONTEFIORE MEDICAL CENTER DEPT. OF ONCOLOGY JUN 22,
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationHST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007
MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationColorectal carcinoma (CRC) was traditionally thought of
Testing for Defective DNA Mismatch Repair in Colorectal Carcinoma A Practical Guide Lawrence J. Burgart, MD Context. Significant bench and clinical data have been generated during the last decade regarding
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationMr Richard Perry. Colorectal Surgeon Christchurch
Mr Richard Perry Colorectal Surgeon Christchurch Colorectal Cancer Richard Perry Ingo Kolossa Alison Ross Judith Collett Craig Lynch Colorectal and General Surgeon Colorectal Surgeon Gastroenterologist
More informationBiomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin)
Recent advances in the management of CRC II 2017/12/17 (Sun.) 10:10-11:00 Biomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin) Department of Clinical
More informationMEDICAL POLICY. SUBJECT: GENOTYPING - RAS MUTATION ANALYSIS IN METASTATIC COLORECTAL CANCER (KRAS/NRAS) POLICY NUMBER: CATEGORY: Laboratory
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationCAP Laboratory Improvement Programs. Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys
CAP Laboratory Improvement Programs Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys Proficiency Survey Results From 2005 to 2012 Theresa A. Boyle,
More information